Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
36.36%
1 month
-9.09%
YTD
7.14%
1 year
-28.57%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
18 October 24 |
$38.5m Funding to Fully Fund Clinical Development Plans
×
$38.5m Funding to Fully Fund Clinical Development Plans |
18 October 24 |
Proposed issue of securities - IRX
×
Proposed issue of securities - IRX |
03 October 24 |
Application for quotation of securities - IRX
×
Application for quotation of securities - IRX |
02 October 24 |
Issue of Shares to CEO in Lieu of Accrued Salary
×
Issue of Shares to CEO in Lieu of Accrued Salary |
02 October 24 |
Proposed issue of securities - IRX
×
Proposed issue of securities - IRX |
30 August 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
31 July 24 |
Jun24 Appendix 4C Cash Flow Report
×
Jun24 Appendix 4C Cash Flow Report |
31 July 24 |
Jun24 Quarterly Activities Report
×
Jun24 Quarterly Activities Report |
25 July 24 |
Live Investor Webinar
×
Live Investor Webinar |
05 July 24 |
IRX616a IND Application Outcome
×
IRX616a IND Application Outcome |
03 July 24 |
Final Clinical Study Report Received, Phase 1 IRX-211
×
Final Clinical Study Report Received, Phase 1 IRX-211 |
06 June 24 |
Change of Director's Interest Notice - Sean Williams
×
Change of Director's Interest Notice - Sean Williams |
03 June 24 |
Notification regarding unquoted securities - IRX
×
Notification regarding unquoted securities - IRX |
31 May 24 |
AGM Results
×
AGM Results |
30 May 24 |
Significant Milestone - IND submitted to the FDA for IRX616a
×
Significant Milestone - IND submitted to the FDA for IRX616a |
30 May 24 |
2024 AGM Slides
×
2024 AGM Slides |
30 April 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
30 April 24 |
AGM Sample Proxy Form
×
AGM Sample Proxy Form |
30 April 24 |
AGM Access Letter
×
AGM Access Letter |
30 April 24 |
Mar24 Quarterly Activities Report
×
Mar24 Quarterly Activities Report |
30 April 24 |
Mar24 Appendix 4C Cash Flow Report
×
Mar24 Appendix 4C Cash Flow Report |
18 April 24 |
Change of Registered Office Address
×
Change of Registered Office Address |
28 March 24 |
$500,000 Convertible Loan Facility
×
$500,000 Convertible Loan Facility |
28 March 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
28 March 24 |
Corporate Governance Statement and Appendix 4G
×
Corporate Governance Statement and Appendix 4G |
28 March 24 |
Appendix 4G
×
Appendix 4G |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.